DOI: 10.1007/s00259-017-3638-zPages: 1079-1091

An update on the role of PET/CT and PET/MRI in ovarian cancer

1. Hospital of the University of Pennsylvania, Department of Radiology

2. Mahidol University, Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital

Correspondence to:
Abass Alavi
Tel: 215-662-3069
Email: abass.alavi@uphs.upenn.edu

Close

Abstract

This review article summarizes the role of PET/CT and PET/MRI in ovarian cancer. With regard to the diagnosis of ovarian cancer, the presence of FDG uptake within the ovary of a postmenopausal woman raises the concern for ovarian cancer. Multiple studies show that FDG PET/CT can detect lymph node and distant metastasis in ovarian cancer with high accuracy and may, therefore, alter the management to obtain better clinical outcomes. Although PET/CT staging is superior for N and M staging of ovarian cancer, its role is limited for T staging. Additionally, FDG PET/CT is of great benefit in evaluating treatment response and has prognostic value in patients with ovarian cancer. FDG PET/CT also has value to detect recurrent disease, particularly in patients with elevated serum CA-125 levels and negative or inconclusive conventional imaging test results. PET/MRI may beneficial for tumor staging because MRI has higher soft tissue contrast and no ionizing radiation exposure compared to CT. Some non-FDG PET radiotracers such as 18F-fluorothymidine (FLT) or 11C-methionine (MET) have been studied in preclinical and clinical studies as well and may play a role in the evaluation of patients with ovarian cancer.

To access the full text, please Sign in

If you have institutional access, please click here

  • Accepted: Jan 24, 2017
  • Online: Feb 8, 2017

Article Tools

eanm
EJNMMI Ad